Thursday is World Ovarian Cancer Day, an annual effort to raise awareness about ovarian cancer, the second most common…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Each May marks Brain Tumor Awareness Month, with annual efforts to raise awareness about glioma and other types of…
Simultaneously blocking the activity of two proteins, LSD1 and GSK3, may be an effective strategy to treat acute myeloid leukemia…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to the cell therapy BCB-276 as a potential…
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Blenrep (belantamab mafodotin) in combination with other medications for…
PANCREATIC CANCER
Drug combo may be effective as treatment for pancreatic cancer
A combination of drugs to block two proteins, called PRMT5 and Chk1, may be effective for the treatment of…
Personalized dosing and monitoring of drug levels may be necessary for children with low-grade glioma treated with Mekinist (trametinib),…
Getting regular exercise can help improve life quality, ease depression, and minimize the risk of medication side effects in people…
PANCREATIC CANCER
Blocking FGFR2 may stop pancreatic cancer from developing
Blocking the activity of a protein called FGFR2 may prevent some pancreatic cancers from developing, a study in mice…
GYNECOLOGICAL CANCER
Trial: Relacorilant aids survival in platinum-resistant ovarian cancer
Adding relacorilant to standard chemotherapy was shown to extend survival among people with platinum-resistant ovarian cancer, meeting the primary…